Galiximab

Galiximab is a monoclonal antibody designed for the treatment of B-cell lymphoma.^[1] As of September 2009^[update], it is undergoing Phase III clinical trials.^[2] The drug is a chimeric antibody from Macaca irus and Homo sapiens.^[3]

Galiximab

Monoclonal antibody
Type	Whole antibody
Source	Chimeric (primate/human)
Target	CD80
Clinical data
ATC code	none
Identifiers
CAS Number	357613-77-5 N
ChemSpider	none
UNII	S9OX9692ZB
KEGG	D04295 Y
NY (what is this?)  (verify)

References

1. Ebadi M, Sadeghi MA, Reddy NM, Rezaei N (2020). "Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma". In Rezaei M (ed.). Cancer immunology: cancer immunotherapy for organ-specific tumors (Second ed.). Cham: Springer Nature. p. 178. ISBN 978-3-03-057949-4.
2. "Biogen Idec: Pipeline". Archived from the original on 2008-05-17. Retrieved 2009-09-24.
3. WHO Drug Information

External links

• Official website